Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Oramed Pharmaceuticals Inc (ORMP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Oramed's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.460 +0.160    +6.96%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
2.470
+0.010
+0.407%
0:05:28 - Real-time Data
  • Volume: 84,376
  • Bid/Ask: 2.410 / 2.480
  • Day's Range: 2.310 - 2.480
Type:  Equity
Market:  United States
Oramed 2.460 +0.160 +6.96%

Oramed Company Profile

 
Read the Oramed company profile to learn more about the business and the management team. View Oramed Pharmaceuticals Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company’s product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Contact Information

Address 1185 Avenue of the Americas 3rd Floor
New York, 10036
United States
Phone 844 967 2633
Fax -

Top Executives

Name Age Since Title
Xiaoming Gao 58 2019 Independent Director
Arie Mayer 66 2019 Independent Director
Jay S. Skyler 75 2020 Member of Scientific Advisory Board
G. Alexander Fleming - 2020 Member of Scientific Advisory Board
Julio Rosenstock - 2020 Member of Scientific Advisory Board
Nadav Kidron 48 2006 President, CEO & Executive Chairman
Avram Hershko 86 2008 Member of Scientific Advisory Board
Leonard Sank 58 2007 Independent Director
Roy Eldor - 2016 Member of the Scientific Advisory Board
Eleuterio Ferrannini - 2007 Member of Scientific Advisory Board
Harold Jacob 69 2008 Member of Scientific Advisory Board
Miriam Kidron 83 2006 Chief Scientific Officer & Director
Anne L. Peters - 2022 Member of Scientific Advisory Board
Benjamin Shapiro 40 2023 Independent Director
Daniel Aghion 42 2024 Independent Director
Yehuda Reznick 76 2024 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ORMP Price Commentary

Write your thoughts about Oramed Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email